Loading stock data…
10x Genomics, Inc. (TXG)
$65.60+2.95 (+4.71%)
Market ClosedLast close Sep 8
10x Genomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
10x Genomics, Inc. in the Healthcare sector is trading at $65.60 with a market capitalization of $8.5B. Wall Street consensus targets $51.00 (14 analysts), implying a -22.3% move over the next 12 months. The stock is currently near its 52-week high of $66.94, remaining 124.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -22.3% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $151.04M↑ | $150.84M↓ | $166.03M↑ | $149.00M↓ | $172.91M |
| Gross Profit | $112.50M↑ | $106.18M↓ | $113.05M↑ | $100.31M↓ | $125.08M |
| Operating Income | -$22.95M↓ | -$17.05M↑ | -$19.54M↑ | -$32.24M↓ | -$10.57M |
| Net Income | -$17.93M↓ | -$13.47M↑ | -$16.25M↑ | -$27.47M↓ | $34.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.10%
Volume
Today's trading volume
3.38M
Recent News
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC Says
10x Genomics (TXG) is offering a compelling product cycle but its two franchises are pulling in oppo
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Str